Important note: Information in this article was accurate in October 2003. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - October 2003
HIVandHepatitis.com
Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
Dyslipidaemia is a common problem affecting HIV-infected patients receiving antiretroviral therapy. Since publication of preliminary guidelines in 2000, numerous studies have addressed the risk of cardiovascular disease, the mechanisms of dyslipidaemia, drug interactions, and the treatment of lipid disorders in HIV-infected patients.
In addition, updated recommendations from the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) have been published that materially affect the clinical approach to lipid disorders in the general population.
A working group of clinical scientists, consisting of members of the Cardiovascular Subcommittee of the AIDS Clinical Trials Group, updated the preliminary recommendations to assist clinicians in the evaluation and treatment of lipid disorders among HIV-infected adults.
Data regarding the prevalence and incidence of dyslipidaemia and cardiovascular disease in HIV-infected patients, pharmacokinetic profiles for hypolipidaemic agents, and treatment trials of dyslipidaemia in HIV-infected patients were considered. Although the implications of dyslipidaemia in this population are not fully known, preliminary data indicate increased cardiovascular morbidity among HIV-infected individuals, suggesting that measures to reduce cardiovascular risk should be provided.
The expert panel recommends that HIV-infected adults undergo evaluation and treatment on the basis of NCEP ATP III guidelines for dyslipidaemia, with particular attention to potential drug interactions with antiretroviral agents and maintenance of virologic control of HIV infection.
When drugs become necessary, the expert panel recommends as initial therapy pravastatin or atorvastatin for elevated low-density lipoprotein cholesterol levels and gemfibrozil or fenofibrate when triglyceride concentrations exceed 500 mg/dL.
Download pdf file of guidelines:
© Copyright 2002 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email publisher@HIVandHepatitis.com).
031010
IB30408-18
©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
